Background: The purpose of this study was to determine clinicopathological correlates of outcome among patients with parotid gland cancer.
Methods: The medical records of 126 patients treated by surgery for localized parotid cancer were retrospectively reviewed to identify the clinicopathologic correlates of recurrence-free survival (RFS) according to histologic grade.
Results: Multivariate analysis revealed that age and lymphovascular invasion were significant factors for recurrence in patients with low-grade cancer (p = .049 and p = .019, respectively), whereas perineural invasion was the only significant factor in patients with high-grade cancer (p = .001). The most frequent recurrence site tends to be different according to histologic grade: local recurrence at low-grade cancer (8.3%) and distant at high-grade cancer (13.6%). The duration of RFS was significantly longer in low-grade cancer than high-grade cancer in regional and distant recurrence (p = .044 and p = .016, respectively).
Conclusion: Consideration of different factors may be required for individual low-grade and high-grade parotid cancers when predicting the risk of recurrence. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1788-E1793, 2016.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.24316 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An 11-gene glycosyltransferases-related model for the prognosis of patients with bladder urothelial carcinoma: development and validation based on TCGA and GEO datasets.
Transl Androl Urol
December 2024
Department of Urology, the First Hospital of Lanzhou University, Lanzhou, China.
Background: Bladder urothelial carcinoma (BLCA) is a highly heterogeneous cancer with a wide range of prognoses, ranging from low-grade non-muscle-invasive bladder cancer (NMIBC), which has a good prognosis but a high recurrence rate, to high-grade muscle-invasive bladder cancer (MIBC), which has a poor prognosis. Glycosylation dysregulation plays a significant role in cancer development. Therefore, this study aimed to investigate the role of glycosyltransferases (GT)-related genes in the prognosis of BLCA and to develop a prognostic model based on these genes to predict overall survival (OS) and assess its clinical application.
View Article and Find Full Text PDFOrgan-sparing partial glansectomy: an alternative surgical management for invasive penile carcinoma-case report.
Transl Androl Urol
December 2024
Department of Urology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, USA.
Background: Penile cancer is a rare malignancy treated via various surgical techniques guided by disease stage and grade with current guidelines suggesting partial or total penectomy for those with pT2 or greater. We report a case of a patient with pT2 squamous cell carcinoma (SCC) of the penis who underwent circumcision with left partial-glansectomy and resection of preputial mass with good oncological control while providing good urinary and sexual function.
Case Description: An 82-year-old male presented to the clinic due to a mass that doubled in size in an 8-month timeframe.
Prophylactic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous tumors with early and limited disease after completely removed.
Medicine (Baltimore)
November 2024
Department of Myxoma, Aerospace Center Hospital, Beijing, China.
The necessity of prophylactic cytoreductive surgery (PCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for low-grade appendiceal mucinous neoplasms (LAMN) after complete removal is still controversial. This study aims to determine the role of PCRS + HIPEC and identify optimal strategies for managing these patients. One hundred fifty-nine patients who sought medical advice at Aerospace Center Hospital were retrospectively analyzed from January 2011 to December 2021.
View Article and Find Full Text PDFFDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Clin Cancer Res
January 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was radiologic overall response rate (ORR), defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.
View Article and Find Full Text PDFIdentification of Key Biomarkers Associated with Glioma Hemorrhage: Evidence from Bioinformatic Analysis and Clinical Validation.
J Mol Neurosci
January 2025
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Hemorrhagic stroke is a known complication of glioma, yet the underlying mechanisms remain poorly understood. This study aims to investigate key biomarkers of glioma-related hemorrhage to provide insights into glioma molecular therapies. Data were obtained from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases to analyze differentially expressed genes (DEGs) in glioma by contrasting glioblastoma (GBM) with low-grade gliomas (LGGs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!